Research and development

News from research

Here you will find recent information on our R&D projects. An overview of our most recent announcements on the progress and results of clinical trials and our latest scientific medical publications are shown here.

Older reports can be found in the archive.

 

Latest news

Solid Tumor Study No. 989 with BT-062 still ongoing

After various inquiries presumable triggered by information in the EU Clinical Trials Register Biotest AG wants to clarify that the Phase I/IIa study with BT-062 in the indications triple negative metastatic breast cancer and metastatic bladder cancer is still ongoing. ... [More]

First patient treated in the next clinical phase III st...

25.01.2017, News

First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP) - Study no. 992 is the second pivotal phase III study ... [More]

Encouraging data of Indatuximab Ravtansine (BT-062) in ...

06.12.2016, News

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma - New data from BT-062 in combination therapy presented at 58th annual conference of ... [More]

Biotest supports a large international retrospective st...

23.11.2016, News

Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation - Results will provide a basis for design of a new ... [More]

First patient treated in global clinical phase III stud...

08.11.2016, News

First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID) - Study no. 991 marks the first phase III study in the ... [More]

Interim analysis supports continuation of clinical phas...

01.11.2016, News

Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990) - Independent Data Safety Monitoring Board (DSMB) recommends to start part ... [More]

Pentaglobin(R) showed a significant survival benefit i...

23.05.2016, News

Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria - Additional therapy with Pentaglobin(R) significantly reduced the relative ... [More]

IgM Concentrate: Remarkable relative reduction in morta...

16.03.2016, News

IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients - Favourable new data of phase II trial with IgM Concentrate in patients with severe ... [More]

Pentaglobin(R) showed encouraging results in the treatm...

14.01.2016, News

Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation - In lung transplantation early new donor specific antibodies (DSA) are ... [More]

Biotest proceeds into phase III programme in congenital...

01.12.2015, News

Biotest proceeds into phase III programme in congenital fibrinogen deficiency - Fibrinogen concentrate shows good efficacy and safety profile based on preliminary data - Preliminary data ... [More]

Biotest to present data from TREAT 2b trial at The Ame...

09.11.2015, News

Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting - Presentation of clinical results from TREAT 2b trial (T cell REgulating ... [More]

Biotest reaches the next milestone in the clinical deve...

06.10.2015, News

Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus ... [More]

Biotest's IgM Concentrate shows encouraging results in ...

30.06.2015, News

Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia - Phase II trial with IgM Concentrate completed in patients with severe community acquired ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mo...

24.04.2015, News

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest proves effective protection from Hepatitis B vi...

23.04.2015, News

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Biotest Presents New Preclinical Data on Tregalizumab (...

18.11.2014, News

Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual Meeting of the American College of Rheumatology in Boston - New preclinical results confirm treatment rationale in ... [More]

Very good results of Civacir(R) (Hepatitis C Immune Glo...

10.11.2014, News

Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial - Preliminary data presented at the Congress of the American Association for the Study of Liver ... [More]

Further preclinical studies emphasise the potential of ...

24.10.2014, News

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of ... [More]